Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii

Chemotherapy
J Garnacho-MonteroJavier Bautista-Paloma

Abstract

A potent synergy of a glycopeptide-colistin combination against Acinetobacter baumannii has recently been described. We set out to assess the efficacy and safety of this combination in a retrospective study including episodes of ventilator-associated pneumonia or bacteremia caused by carbapenem-resistant A. baumannii. We compared 29 patients (group I) treated with colistin plus vancomycin with 28 patients treated with colistin alone (group II). Group I received vancomycin (for empirical or targeted therapy) at the onset of colistin administration and both antimicrobials coincided for at least 5 days. Baseline characteristics, clinical cure, microbiological eradication, and mortality were similar in both groups but the rate of acute kidney injury was higher in group I (55.2 vs. 28%; p = 0.04). In critically ill patients with carbapenem-resistant A. baumannii infections, clinical outcomes do not differ in patients treated with colistin plus vancomycin from those receiving colistin without vancomycin. This combination significantly increases the risk of renal failure.

Citations

Sep 5, 2014·Current Opinion in Critical Care·Ignacio Martín-LoechesJordi Vallés
Apr 14, 2015·Expert Review of Anti-infective Therapy·José Garnacho-MonteroAntonio Gutiérrez-Pizarraya
Apr 29, 2014·Expert Opinion on Pharmacotherapy·Ilias Karaiskos, Helen Giamarellou
Feb 24, 2015·Current Medical Research and Opinion·Abed Zahedi Bialvaei, Hossein Samadi Kafil
Dec 10, 2015·Infectious Diseases and Therapy·Phillip J BergenBrian T Tsuji
Jul 27, 2015·Current Opinion in Pharmacology·Pierluigi VialeRussell Lewis
Sep 30, 2015·Journal of Microbiological Methods·Gabriel A March, Miguel A Bratos
Oct 7, 2015·Intensive Care Medicine·José Garnacho-MonteroUNKNOWN European Society of Intensive Care Medicine
Nov 26, 2015·Scientific Reports·Zhijin ChenXungang Xiao
Feb 20, 2015·Applied Microbiology and Biotechnology·Jaejoon Jung, Woojun Park
Jan 30, 2015·Pharmacotherapy·Phillip J BergenBrian T Tsuji
Sep 9, 2015·Current Opinion in Critical Care·Cristina Vazquez Guillamet, Marin H Kollef
Jun 21, 2015·Current Infectious Disease Reports·Kristina L Bailey, Andre C Kalil
Feb 24, 2015·Journal of Intensive Care·Mohan Gurjar
May 28, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N L ParchemC V Murphy
Nov 29, 2014·BMC Infectious Diseases·José Garnacho-MonteroLuis Martin-Villen
Aug 24, 2016·Current Opinion in Critical Care·Nina M ClarkJoseph P Lynch
Sep 15, 2016·The Journal of Antimicrobial Chemotherapy·Oren ZusmanMical Paul
Aug 31, 2016·Expert Opinion on Drug Metabolism & Toxicology·Ilias KaraiskosHelen Giamarellou
Nov 28, 2017·Expert Review of Anti-infective Therapy·Ilias KaraiskosHelen Giamarellou
Dec 16, 2016·Clinical Microbiology Reviews·Darren WongBrad Spellberg
Dec 7, 2018·Current Opinion in Infectious Diseases·José Garnacho-Montero, Jean-François Timsit
Mar 6, 2017·Infectious Diseases and Therapy·Eric WenzlerEllie J C Goldstein
Sep 15, 2017·Bioscience Trends·Yun YuShuming Pan
Mar 6, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Alessandra OlivaRino Ragno
Oct 8, 2016·Annals of Intensive Care·Gabor ZilahiIgnacio Martin-Loeches
Dec 29, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Florian WagenlehnerJason M Pogue
Mar 13, 2021·Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine·Samir SamalDiganta Mohanty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.